Clinical trial
Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
NCT03295565
Study timeline
Study start (actual)2017-05-07Date precision: day
Registry last updated2022-04-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancer Metastaticunresolved
Metastasisunresolved
Interventions
CabazitaxelDRUG · verified · RxNorm: cabazitaxel
AbirateroneDRUG · verified · RxNorm: abiraterone
EnzalutamideDRUG · verified · RxNorm: enzalutamide
Sponsors & collaborators
The Netherlands Cancer Institutelead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03295565 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.